Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8628754 | ACORDA | Highly efficient delivery of a large therapeutic mass aerosol |
Jun, 2020
(3 years ago) | |
US6921528 | ACORDA | Highly efficient delivery of a large therapeutic mass aerosol |
Jun, 2020
(3 years ago) | |
US6514482 | ACORDA | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(3 years ago) | |
US6613308 | ACORDA | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(3 years ago) | |
US6979437 | ACORDA | Pulmonary delivery in treating disorders of the central nervous system |
Sep, 2020
(3 years ago) | |
US7146978 | ACORDA | Inhalation device and method |
Apr, 2021
(3 years ago) | |
US6858199 | ACORDA | High efficient delivery of a large therapeutic mass aerosol |
Nov, 2021
(2 years ago) | |
US7556798 | ACORDA | Highly efficient delivery of a large therapeutic mass aerosol |
Nov, 2021
(2 years ago) | |
US7384649 | ACORDA | Particulate compositions for pulmonary delivery |
Nov, 2022
(1 year, 5 months ago) | |
US9155699 | ACORDA | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 1 month ago) | |
US8586093 | ACORDA | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 1 month ago) | |
US8404276 | ACORDA | Pulmonary delivery for levodopa |
Mar, 2023
(1 year, 1 month ago) | |
US7182961 | ACORDA | Particulate compositions for pulmonary delivery |
Feb, 2024
(2 months ago) | |
USRE43711 | ACORDA | Pulmonary delivery for levodopa |
Feb, 2029
(4 years from now) | |
US8945612 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
US8545878 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
US9393210 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) | |
US8685442 | ACORDA | Capsules containing high doses of levodopa for pulmonary use |
Nov, 2032
(8 years from now) |
Inbrija is owned by Acorda.
Inbrija contains Levodopa.
Inbrija has a total of 18 drug patents out of which 13 drug patents have expired.
Expired drug patents of Inbrija are:
Inbrija was authorised for market use on 21 December, 2018.
Inbrija is available in powder;inhalation dosage forms.
Inbrija can be used as intermittent treatment of off episodes in patients with parkinson's disease with a powder inhaler, intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles, intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step.
The generics of Inbrija are possible to be released after 16 November, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 21, 2021 |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step; Intermitt...
Dosage: POWDER;INHALATION